Entering text into the input field will update the search result below

BioNTech: Profit Off Of Next-Gen Vaccines And Therapies

Jan. 05, 2022 12:03 AM ETBioNTech SE (BNTX) StockMRNA26 Comments
Star Investments profile picture
Star Investments


  • This stock is a bet on the idea that BioNTech can become a Next-Gen drug development platform able to develop new solutions to attack infectious diseases, cancer, and other conditions.
  • BioNTech, unlike Moderna, is not exclusively an mRNA platform company. BioNTech is building out multiple platforms that include an Antibody platform, a Cell Therapies platform, and a Small Molecule Immunomodulators platform.
  • Q3 2021 total revenues were estimated to be approximately €6.1 billion for Q3 2021, compared to €67.5 million for the comparative period in 2020.
  • One major risk with BioNTech's mRNA franchise is numerous companies having patent claims to the technology. BioNTech has already been sued over certain aspects of mRNA technology.
  • BioNTech is a buy but only for very aggressive investors that are willing to speculate on the company's emerging vaccine and therapy pipeline.

Headquarters of the company Biontech in Mainz, Germany

U. J. Alexander/iStock Editorial via Getty Images

BioNTech (NASDAQ: NASDAQ:BNTX) is a high risk, high reward speculative investment, The stock is a bet on the idea that BioNTech can become a drug development platform in which it can

This article was written by

Star Investments profile picture
I have been a Merchant Seaman that has traveled the world for over 30 years. Within the last 15 years, I developed a very intense interest in investing. I learned a lot of what I know about investing from The Motley Fool. Also because I have a engineering background, I often tend to gravitate to Tech stocks

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BNTX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (26)

R0ckS0lid profile picture
Buy the dip. Despite all the anti-vac news, many People still want to be boosted because they stay want to stay out of the hospital and to avoid very unpleasant symptoms. Omicron specific vaccine will also be desirable by many. Bottom line is BioNTech will continue to bring in strong revenue and profit. Their evaluation is cheap, and there are no insider selling or note selling to deplete its value. The upside is huge if Omicron specific vaccine is a hit, or one of their pipeline comes through.
SelinMelis profile picture
I can underline the sentence "BioNTech is a stock for long-term investors who are looking for a very high price potential".

BUT I don't think the word "speculate" is really appropriate in connection with BioNTech.

If you take a closer look at the career of Prof. Dr. Dr. Sahin and his wife Dr. Türeci, you can't think of a more suitable person to invest your money in.

Without going too deeply into the matter. What do the biggest companies of our time all have in common?They had visionary management, world class products with high gross margins and money to grow.

1. Visionary management. Definitely. Take time and compare. There is just one Prof. Dr. Dr. Sahin.

2. First-class products. See COVID vaccine with 94% protection.

3. Money to grow.With the vaccine revenue, BioNTech is now in excellent shape to support all of its growth initiatives.

4. Many think that BioNTech's new drugs will take many years to get their approval. I don't think so.

Almost all of the drugs in BioNTech's pipeline meet the requirements for accelerated approval. www.fda.gov/...

BioNTech's BNT111 has already received it. edition.cnn.com/...
This is one of the best article I have read. It is a very balanced view of how the company will perform in the future and the risk associated in investing in the company. One of the issue that needs clarification is The cost of producing one dose of vaccine and the Price it fetches? Could you elaborate on that to give us a colour on the profitability of the vaccine?
R0ckS0lid profile picture
They have the cash and reputation to partner with others to do it.

“BioNTech said it would likely generate up to 17 billion euros ($19 billion) in 2022 revenue from the COVID-19 vaccine it co-developed with Pfizer, pledging to spend earnings on development of cancer drugs and new vaccines”.


In addition to more projects with Pfizer, BioNTech is collaborating with others like Crescendo Bio to develop multi-specific precision immunotherapies


Despite the billions of profits, there are no insider selling.

Hold this stock or buy the dips!
The are going to have competition from Omicron. And soon when detailed data about vax will be released might have legal problems. I refer to US judge verdict. Not even talking about children risk/benefit of vax.
Enjoyed reading this I've bought BNTX several years ago an held on (a pleased EU based) shareholder, not sure i'd add more today. As Covid continues to mutate MRNA tech is one of the best shots out there (no pun intended) - so the other uses " future music" is not the main driver for me. There's still plenty of cash flow in covid. That said VALN is looking attractive in EU after recent sell-off - also because investors are not aware that it is one of the best alternative Vaccine plays (I bought it pre-covid for the vaccine against lime disease). Since we will continue to treat the unvaccinated, a much less known Dutch Biotech as a medication against the inflammatory response (PHAR) that can save lives once in the hospital. They are already profitable today with other products. I'm long both ...full disclosure
@baseless Several years? Are you telling us the truth? The IPO was in October 2019. And if you really are an early investor, you should know more about the company than your post suggests...
@User 25188403 i bought not long after the IPO…not pre IPO
Does anyone have any technical arguments about where the stock price is headed? I am long BNTX, but not buying dips just to buy dips. Is 200 a resistance point?
@TimeKop It's an extremely volatile stock. Buying and holding while trading bullish options is working for me. 220-230 has been resistance for a while, check the chart. It tested below 200 which surprised me but as you can see, it doesn't take much to bounce back.
Very good article, thank you.

I have been buying the dips for quite a while now, this is such a great company for my retirement portfolio.

I live in Germany, so I get a lot of detailed info just by browsing our news.

Whoever is trying to crash it, please drop it even more.

I have a lot more money to buy.
@Vanadas same here…looking to add if it gets cheaper…bought it cheap once…happy to add more
German companies focus and then do very well in that area (think german car and technical companies). BNTX is German focus with Turkish entrepreneurial spirit. I'm in this company for the long haul. Their main HQ is near where I live and the buzz is continuously positive. I'm glad they don't only put their eggs into the MRNA basket - good risk management to have more technologies.
charly333 profile picture
BNTX is very attractive mainly because of the mRNA technology and successful researchers in this field. It is interesting to read about who was researching mRNA in the past. Read about the amazing Katalin Kariko. She is working with Biontech since 2014.
A good start to read about mRNA history is here:

I was trading BNTX in the past and recently took a small position again. I would like to see lower prices before buying more because the stock at the moment is dependent on Covid news. Best should be to build a long term position slowly.
If MRNA and BNTX are successful in developing a Covid-Flu combo vaccination this could be a good revenue with advantages for mRNA capable firms for the years when the pandemic is over. Because they could develop and market new flu viruses faster they could gain in this field.
Star Investments profile picture
@charly333 I think you might be saying that mostly because of unfamiliarity with some of the other things they are researching. The company is pursuing some other cool things outside of mRNA that could potentially be blockbusters, especially the research being done into antibodies.
@charly333 But we need to separate Moderna from BioNTech Moderna have cap of 100 and BioNTech 50
We should think like we did with Nokia and Apple around 2010
charly333 profile picture
@Star Investments You are right. I can not judge the value of their traditional research. But I am sure there they will have more competition. I am happy with a broad approch. They have the money now to do so.
Very clear and give the right idees and risk for the future
Biontech have several More agreements like Sanofi etc
The company should have simular future as Tesla when they where in early stage back in 2014
@Cgfridh totally agree and also mRNA technology optimized from complex to easy use....just amazing....and they will also do smart buy in with this cash status
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About BNTX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BNTX

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.